Related Experiment Video
Updated: Mar 1, 2026

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
Published on: June 10, 2025
A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib
Joseph Gabriel Gabriel1, Aaysha Kapila1, Alexei Gonzalez-Estrada1
1East Tennessee State University, Johnson City, TN, USA.
Abstract:
Phosphatidylinositol 3-kinase δ (PIK3δ) is a tyrosine kinase essential for B cell survival, making it an important target in the treatment of chronic lymphocytic leukemia. Idelalisib is an inhibitor of PIK3δ demonstrating initial success in disease response, but is now shown to have a decreased overall survival and life-threatening serious adverse events. The following is an unfortunate case of a grade III adverse skin reaction secondary to idelalisib with the likely complication of methicillin-resistant Staphylococcus aureus bacteremia.
Related Concept Videos
Drug Toxicity: Allergic Reactions
Drug toxicity: Idiosyncratic Reactions
Hypersensitivity Reactions: Cytolytic Reactions
Allergic Drug Reactions
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...